Cetuximab News and Research

RSS
Cetuximab is an investigational IgG1 monoclonal antibody designed to target and block the Epidermal Growth Factor Receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types. Cetuximab is designed to bind to EGFR and prevent natural ligands called growth factors from binding to the receptor and inducing phosphorylation, i.e., activation of signaling to the tumor. The most common drug-related adverse events reported in clinical trials of cetuximab have been an acne-like rash and asthenia. Severe allergic reactions may occur in a small percentage of patients.
Intensity-modulated radiation therapy reduces radiation exposure to heart and lungs in NSCLC patients

Intensity-modulated radiation therapy reduces radiation exposure to heart and lungs in NSCLC patients

The Clinical Importance of Circulating Tumor DNA

The Clinical Importance of Circulating Tumor DNA

Phase 1 clinical trial underway to test City of Hope-developed cancer treatment

Phase 1 clinical trial underway to test City of Hope-developed cancer treatment

Researchers investigate the efficacy of a novel intra-tumoral drug delivery carrier in treating oral squamous cell carcinoma

Researchers investigate the efficacy of a novel intra-tumoral drug delivery carrier in treating oral squamous cell carcinoma

Cetuximab plus radiotherapy effective in treating locally advanced cutaneous squamous cell cancer

Cetuximab plus radiotherapy effective in treating locally advanced cutaneous squamous cell cancer

Patient-derived head and neck cancer organoids could aid the discovery of novel therapies

Patient-derived head and neck cancer organoids could aid the discovery of novel therapies

New combination therapy shows promising results in some patients with advanced head and neck cancer

New combination therapy shows promising results in some patients with advanced head and neck cancer

CAR T-cell therapy in colorectal cancer

CAR T-cell therapy in colorectal cancer

MIT chemists discover how changes in a shape-shifting receptor trigger cell growth

MIT chemists discover how changes in a shape-shifting receptor trigger cell growth

Salk study could help find better treatment options for colorectal cancer patients

Salk study could help find better treatment options for colorectal cancer patients

Topical therapy can help safely reduce side effect of cancer treatment

Topical therapy can help safely reduce side effect of cancer treatment

Salk joins a long list of recipients included in The Conrad Prebys Foundation’s inaugural grant cycle

Salk joins a long list of recipients included in The Conrad Prebys Foundation’s inaugural grant cycle

Proteogenomics can help determine effective treatment for head and neck squamous cell carcinoma

Proteogenomics can help determine effective treatment for head and neck squamous cell carcinoma

First comparative data of encorafenib and paradox breaker inhibitors in BRAF mutant CRC

First comparative data of encorafenib and paradox breaker inhibitors in BRAF mutant CRC

Turning autoimmunity drugs into anti-cancer treatments

Turning autoimmunity drugs into anti-cancer treatments

Immunotherapy doubles progression-free survival time of patients with advanced bowel cancer

Immunotherapy doubles progression-free survival time of patients with advanced bowel cancer

SU2C commends FDA’s approval of new cancer therapy

SU2C commends FDA’s approval of new cancer therapy

Study: Chemoradiation regimen for Stage III NSCLC is better than two tested alternatives

Study: Chemoradiation regimen for Stage III NSCLC is better than two tested alternatives

Understanding Monoclonal Antibody Unfolding and Aggregation

Understanding Monoclonal Antibody Unfolding and Aggregation

Study: Checkpoint inhibitor prolongs survival in patients with head and neck cancers

Study: Checkpoint inhibitor prolongs survival in patients with head and neck cancers